Industry
Biotechnology
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
6.41
Mkt cap
538M
Volume
1.3M
High
6.64
P/E Ratio
-2.59
52-wk high
19.34
Low
6.02
Div yield
N/A
52-wk low
4.30
Portfolio Pulse from Kaustubh Bagalkote
May 28, 2024 | 11:29 am
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 6:55 pm
Portfolio Pulse from Benzinga Insights
April 23, 2024 | 8:31 pm
Portfolio Pulse from Avi Kapoor
April 11, 2024 | 12:46 pm
Portfolio Pulse from Benzinga Neuro
April 05, 2024 | 3:03 am
Portfolio Pulse from Benzinga Newsdesk
April 03, 2024 | 12:47 pm
Portfolio Pulse from Avi Kapoor
April 02, 2024 | 5:23 pm
Portfolio Pulse from Benzinga Insights
April 02, 2024 | 4:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.